Trials / Available
AvailableNCT03773770
Expanded Access to Triheptanoin
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Ultragenyx Pharmaceutical Inc · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Expanded access may be provided for qualified patients who have limited treatment options and are not eligible for a clinical trial.
Detailed description
Long Chain Fatty Acid Oxidation Disorders (LC-FAOD) and other Non-FAOD conditions, where applicable: Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies. For full details, please visit the links provided below.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triheptanoin | Liquid for oral (PO) or enteral tube administration |
Timeline
- First posted
- 2018-12-12
- Last updated
- 2026-04-13
Source: ClinicalTrials.gov record NCT03773770. Inclusion in this directory is not an endorsement.